Literature DB >> 3157296

Paroxetine in the treatment of depression--a randomized comparison with amitriptyline.

A L Laursen, P L Mikkelsen, S Rasmussen, P le Fèvre Honoré.   

Abstract

Paroxetine is a new antidepressant drug with potent serotonin (5HT) uptake inhibitory properties. In this double-blind comparative study, the antidepressant effect of paroxetine and amitriptyline has been compared in 44 patients with depressive illnesses of an endogenous nature. Each drug was given for 6 weeks. The 17-item Hamilton Depression Scale was used to measure the antidepressant effect. Reported events were assessed applying a 22-item check list. Non-parametric statistical analyses were applied in the evaluation of treatment outcome for the 30 patients who completed the study. The results showed no significant differences in overall antidepressant efficacy between paroxetine and amitriptyline and that paroxetine displayed significantly fewer instances of dry mouth and orthostatic dizziness than amitriptyline. No obvious relationship was demonstrated between the plasma levels of the drugs and their clinical effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157296     DOI: 10.1111/j.1600-0447.1985.tb01281.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  15 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.

Authors:  E Trindade; D Menon; L A Topfer; C Coloma
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

3.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  D R Thomas; D R Nelson; A M Johnson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 4.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.

Authors:  I M Anderson; B M Tomenson
Journal:  BMJ       Date:  1995-06-03

6.  Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study.

Authors:  Inbar Zucker; Gabriel Chodick; Leon Grunhaus; Ra'anan Raz; Varda Shalev
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

7.  Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study.

Authors:  C-Y Wang; S-H Fu; C-L Wang; P-J Chen; F-L L Wu; F-Y Hsiao
Journal:  Osteoporos Int       Date:  2015-07-01       Impact factor: 4.507

Review 8.  Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.

Authors:  S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

9.  Use of anti-depressants and the risk of fracture of the hip or femur.

Authors:  M W M van den Brand; S Pouwels; M M Samson; T P van Staa; B Thio; C Cooper; H G M Leufkens; A C G Egberts; H J J Verhaar; F de Vries
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

10.  Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.

Authors:  F Song; N Freemantle; T A Sheldon; A House; P Watson; A Long; J Mason
Journal:  BMJ       Date:  1993-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.